SRR1316815
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.419
- MYOGENESIS+0.390
- PANCREAS_BETA_CELLS+0.286
- APICAL_SURFACE+0.256
- APICAL_JUNCTION+0.241
- HEDGEHOG_SIGNALING+0.199
- SPERMATOGENESIS+0.188
- UV_RESPONSE_DN+0.159
- ESTROGEN_RESPONSE_LATE+0.122
- ESTROGEN_RESPONSE_EARLY+0.078
Top 10 suppressed
- MYC_TARGETS_V1-0.602
- E2F_TARGETS-0.517
- G2M_CHECKPOINT-0.497
- UNFOLDED_PROTEIN_RESPONSE-0.484
- PROTEIN_SECRETION-0.478
- IL6_JAK_STAT3_SIGNALING-0.448
- TNFA_SIGNALING_VIA_NFKB-0.386
- MTORC1_SIGNALING-0.371
- TGF_BETA_SIGNALING-0.346
- DNA_REPAIR-0.338
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1431307 | GTEX | — | 0.960 |
| 2 | SRR1439807 | GTEX | — | 0.957 |
| 3 | SRR1391922 | GTEX | — | 0.947 |
| 4 | SRR1323043 | GTEX | — | 0.947 |
| 5 | SRR1341277 | GTEX | — | 0.942 |
| 6 | SRR1337864 | GTEX | — | 0.941 |
| 7 | SRR1475168 | GTEX | — | 0.941 |
| 8 | SRR1392985 | GTEX | — | 0.939 |
| 9 | SRR1464451 | GTEX | — | 0.938 |
| 10 | SRR1471350 | GTEX | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.419 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.286 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.256 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.241 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.199 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.188 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.159 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.122 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.078 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.073 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.066 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.057 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.046 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.037 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.025 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.017 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.005 | Inavolisib | — uncovered |